Oncology is currently witnessing an unprecedented era of innovation. The convergence of targeted therapies, immunotherapies, and precision medicine is fundamentally altering the prognosis for patients with previously intractable cancers. Yet, as the pace of scientific discovery accelerates, a profound disconnect has emerged within the healthcare ecosystem: a widening chasm between the pristine, controlled environment of clinical trials and the complex, messy, and multifaceted reality of routine clinical practice.
While clinical trials remain the gold standard for establishing drug safety and efficacy, they are increasingly insufficient in isolation. To truly optimize patient outcomes, the oncology sector must embrace "real-world evidence" (RWE)—a bridge that connects the promise of new therapies with the actual experiences of patients in the community.
The Foundation: Why Clinical Trials Are Only the Beginning
Clinical trials are designed to answer specific, narrow questions under rigid conditions. By design, they enroll "ideal" candidates—typically younger, healthier individuals with fewer comorbidities and standardized treatment histories. This approach is essential for regulatory approval, as it minimizes "noise" and isolates the therapeutic effect of a new molecule.
However, the patient who walks into a community oncology clinic rarely resembles the participant in a Phase III trial. In the real world, clinicians treat patients who are often older, manage multiple chronic conditions, navigate fragmented care systems, and face socioeconomic barriers that directly impact their health trajectory. When a drug leaves the clinical trial setting, it enters a landscape of biological, logistical, and social variables that the original trial protocol simply did not account for.
Chronology of an Evolution: From Anecdote to Evidence
For decades, the transition of a therapy from trial to practice was governed largely by clinical judgment and anecdotal experience.
- The Pre-Data Era: Historically, once a drug was approved, physicians relied on the trial’s topline results and their own intuition to determine how to sequence therapies. This often led to "off-label" use based on limited experience.
- The Digital Transformation: As electronic health records (EHRs) became ubiquitous, the volume of oncology data exploded. However, this data remained trapped in silos—unstructured notes, fragmented registries, and disconnected databases.
- The Rise of Real-World Data (RWD): Over the last decade, the industry recognized that if this fragmented data could be curated and standardized, it could become a powerful tool.
- Regulatory Maturation: Recognizing the limitation of trials, global regulators, including the FDA, began issuing guidance on how RWE could support regulatory decision-making, acknowledging its role in evaluating safety and effectiveness in broader populations.
The Clinical Necessity: Understanding Complexity
The necessity for RWE is rooted in the biological and demographic diversity of the oncology patient population. Tumor biology is rarely monolithic; even two patients with the same histological diagnosis may possess distinct biomarker profiles that render one drug highly effective for one and useless for another.
Addressing the "Sequencing" Challenge
One of the most persistent clinical dilemmas is determining the optimal sequence of therapies. In a trial, patients might receive a drug as a first-line treatment. In the real world, that patient may have already exhausted several lines of therapy or have a unique comorbidity profile. RWE provides the longitudinal visibility necessary to observe how different sequences perform in the real world, allowing clinicians to make evidence-based decisions rather than relying on extrapolation.
Identifying Patterns in Heterogeneous Populations
RWE serves as a feedback loop. By analyzing outcomes across diverse demographics—including those underrepresented in trials—researchers can identify which patient profiles derive the most benefit. This allows for a more personalized approach to oncology, where treatment strategies are tailored to the specific characteristics of the individual.
Supporting Data: Building a More Complete Value Proposition
The value of RWE extends far beyond the examination room. It provides a multi-dimensional lens through which the entire healthcare ecosystem views oncology:
- For Payers and Health Systems: RWE is crucial for value-based care. Payers require more than just trial efficacy; they need to understand the "real-world" durability of a response and the total cost of care. Without robust RWE, value assessments are often incomplete, leading to potential misalignments in reimbursement and patient access.
- For Researchers: RWE acts as a perpetual clinical study. It highlights gaps in current care—such as persistent toxicities or unexpected treatment failures—that can inform the design of future clinical trials, ensuring that the next generation of studies addresses the most pressing unmet needs.
- For Regulators: RWE provides a critical safety net. It confirms that the efficacy and safety signals observed in the "clean" environment of a trial hold steady in the "unselected" population of the real world, providing an extra layer of post-market surveillance.
The Criticality of Data Integrity
The power of RWE is entirely dependent on the quality of the underlying data. Oncology data is inherently complex, involving staging, molecular biomarkers, granular treatment histories, and longitudinal outcomes. Simply aggregating data from an EHR is insufficient.
To be actionable, this data must undergo rigorous curation. This includes:
- Clinical Contextualization: Raw data, such as a lab result, is meaningless without clinical context. It must be mapped to standardized frameworks (like those used in clinical oncology).
- Longitudinal Integration: Data must be linked over time to reflect the patient’s entire journey, not just a snapshot.
- Validation: Ongoing audits are required to ensure that the data is accurate, complete, and representative of the clinical reality.
Without this level of rigor, the "evidence" generated is merely noise. Organizations that prioritize intentional data curation are the ones that will successfully bridge the gap between innovation and practice.
Addressing Disparities: The Human Impact
Perhaps the most compelling argument for RWE is its potential to improve equity in cancer care. By analyzing real-world outcomes, we can uncover disparities in how different populations access and respond to treatments.
When evidence reflects the true diversity of the patient population, it becomes a diagnostic tool for identifying where the system is failing specific groups. Whether it is a lack of access to clinical trials or differences in how treatments are administered, RWE shines a light on these inequalities, providing the necessary evidence to advocate for more tailored, equitable approaches to treatment.
Implications for the Future
As oncology continues to advance, the role of RWE will only expand. We are moving toward a future where the distinction between a "trial" and "real-world care" becomes more porous. Future clinical trials may increasingly incorporate real-world control arms, and treatment protocols may be dynamically updated based on the constant stream of evidence coming from the clinic.
However, the industry must be cautious. RWE does not replace clinical trials; it extends their value. The future of oncology lies in the synergy between the two. By connecting the scientific innovation of the trial environment with the lived reality of the clinic, we ensure that every breakthrough translates into a meaningful, measurable improvement in patient outcomes.
For the clinician, the researcher, and the patient, the goal remains the same: ensuring that the right patient receives the right treatment at the right time. In an era of rapid complexity, high-quality, clinically grounded real-world evidence is the compass that will help us navigate that path.
About the Author
C.K. Wang, MD
General Manager of Oncology and Chief Medical Officer at Verana Health
Dr. C.K. Wang is a leader in the intersection of oncology and digital health. Having served as the Chief Medical Officer and CEO of COTA before its merger with Verana Health, he has been a pioneer in creating real-world solutions for hematologic oncology. With a career spanning over 12 years in clinical practice and leadership roles at IBM Watson Health, Dr. Wang brings a deep understanding of both the patient experience and the technological infrastructure required to advance cancer care. He is board-certified in medical oncology and continues to advocate for the use of clinically rich, longitudinal data to transform the oncology landscape.
